NO20051225L - 1,2,4- oksadiazoler som modulatorer av metabotropisk glutamat-reseptor-5 - Google Patents
1,2,4- oksadiazoler som modulatorer av metabotropisk glutamat-reseptor-5Info
- Publication number
- NO20051225L NO20051225L NO20051225A NO20051225A NO20051225L NO 20051225 L NO20051225 L NO 20051225L NO 20051225 A NO20051225 A NO 20051225A NO 20051225 A NO20051225 A NO 20051225A NO 20051225 L NO20051225 L NO 20051225L
- Authority
- NO
- Norway
- Prior art keywords
- oxadiazoles
- modulators
- glutamate receptor
- metabotropic glutamate
- compounds
- Prior art date
Links
- 150000005071 1,2,4-oxadiazoles Chemical class 0.000 title 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40204002P | 2002-08-09 | 2002-08-09 | |
| PCT/US2003/024846 WO2004014881A2 (fr) | 2002-08-09 | 2003-08-08 | Nouveaux composes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20051225L true NO20051225L (no) | 2005-05-09 |
Family
ID=31715777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051225A NO20051225L (no) | 2002-08-09 | 2005-03-09 | 1,2,4- oksadiazoler som modulatorer av metabotropisk glutamat-reseptor-5 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20040152699A1 (fr) |
| EP (1) | EP1529045A2 (fr) |
| JP (2) | JP4637578B2 (fr) |
| KR (1) | KR20050033070A (fr) |
| CN (2) | CN101723941A (fr) |
| AR (1) | AR040847A1 (fr) |
| AU (1) | AU2003259068B2 (fr) |
| BR (1) | BR0313265A (fr) |
| CA (1) | CA2494987C (fr) |
| IL (1) | IL166510A0 (fr) |
| IS (1) | IS7733A (fr) |
| MX (1) | MXPA05001594A (fr) |
| NO (1) | NO20051225L (fr) |
| NZ (1) | NZ538225A (fr) |
| PL (1) | PL375256A1 (fr) |
| RU (1) | RU2352568C9 (fr) |
| TW (1) | TWI341314B (fr) |
| UA (1) | UA87653C2 (fr) |
| WO (1) | WO2004014881A2 (fr) |
| ZA (1) | ZA200500886B (fr) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014881A2 (fr) * | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | Nouveaux composes |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005077345A1 (fr) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Composes pour le traitement de la maladie du reflux gastro-oesophagien |
| AU2005214375A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| TW200538108A (en) | 2004-02-19 | 2005-12-01 | Astrazeneca Ab | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| ATE451364T1 (de) * | 2004-02-23 | 2009-12-15 | Glaxo Group Ltd | Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate |
| JP2007530589A (ja) * | 2004-03-26 | 2007-11-01 | アンフォラ ディスカバリー コーポレーション | 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用 |
| CN101014578B (zh) | 2004-09-16 | 2011-01-19 | 安斯泰来制药有限公司 | 三唑衍生物或其盐 |
| JP4557685B2 (ja) | 2004-11-15 | 2010-10-06 | 独立行政法人理化学研究所 | 蛍光蛋白質 |
| KR20070084574A (ko) * | 2004-12-01 | 2007-08-24 | 칼립시스, 인코포레이티드 | 유도가능 산화질소 신타제 이량체화 억제제 |
| ES2346685T3 (es) * | 2005-01-14 | 2010-10-19 | F. Hoffmann-La Roche Ag | Deribados de tiazol-4-carboxamida como antagonistas de mglur5. |
| JPWO2006080533A1 (ja) * | 2005-01-31 | 2008-06-19 | 持田製薬株式会社 | ３−アミノ−１，２，４−トリアゾール誘導体 |
| GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| WO2007062410A1 (fr) * | 2005-11-28 | 2007-05-31 | Kalypsys, Inc. | Dérivés d’imidazole comme inhibiteur de la dimérisation de l’oxyde nitrique synthase |
| TW200811157A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| EP2272509A1 (fr) | 2006-09-11 | 2011-01-12 | Novartis AG | Nouvelles utilisations des récepteurs du glutamate métabotropique |
| TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
| RU2009127095A (ru) * | 2006-12-15 | 2011-01-20 | Эбботт Лэборетриз (Us) | Новые оксадиазольные соединения |
| US20110207704A1 (en) * | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
| EP1958631A1 (fr) * | 2007-02-14 | 2008-08-20 | AEterna Zentaris GmbH | Nouveaux dérivés de triazole en tant que ligands de récepteurs couplés à la protéine G |
| US20100144756A1 (en) | 2007-07-13 | 2010-06-10 | Bolea Christelle | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| ES2655466T3 (es) | 2007-08-13 | 2018-02-20 | Monsanto Technology Llc | Composiciones y procedimientos de control de nematodos |
| WO2009051705A1 (fr) * | 2007-10-18 | 2009-04-23 | Merck & Co., Inc. | 1,2,4-oxadiazoles substitués et leurs analogues comme modulateurs des récepteurs cb2, utiles dans le traitement de la douleur et de maladies respiratoires et non respiratoires |
| BRPI0818448A2 (pt) * | 2007-10-19 | 2015-05-12 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5. |
| WO2009054785A1 (fr) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Dérivés d'éther de 1,2,4-triazole comme modulateurs de mglur5 |
| WO2009133389A1 (fr) * | 2008-04-28 | 2009-11-05 | Astrazeneca Ab | Procédés destinés à la préparation d’hétérocycles substitués |
| WO2009147190A1 (fr) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Nouveaux composés |
| WO2009147188A1 (fr) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Dérivés de benzpyrazole en tant qu'inhibiteurs de p13 kinases |
| JP5502076B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規化合物 |
| EP2288607B1 (fr) | 2008-06-09 | 2014-09-24 | Sanofi | Sulfonamides comprenant un hétérocycle et un groupe de tête oxadiazolone, procédés pour les préparer et leur utilisation comme produits pharmaceutiques |
| WO2010000763A2 (fr) | 2008-06-30 | 2010-01-07 | Novartis Ag | Produits de combinaison |
| ES2620657T3 (es) | 2008-07-03 | 2017-06-29 | Astellas Pharma Inc. | Derivado de triazol o sal del mismo |
| DE102009041241A1 (de) | 2009-09-11 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102009041242A1 (de) | 2009-09-11 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102008057343A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102008057364A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102008057344A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
| US20110313172A1 (en) * | 2008-12-18 | 2011-12-22 | Astrazeneca Ab | Process for the preparation of 1-[5-(3-chloro-phenyl)-isooxazol-3-yl]-ethanone and (r)-1-[5-(3-chloro-phenyl)-isooxazol-3-yl]-ethanol |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| RS53830B1 (sr) | 2009-04-30 | 2015-06-30 | Glaxo Group Limited | Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze |
| EP2438052A1 (fr) * | 2009-06-05 | 2012-04-11 | Oslo University Hospital HF | Dérivés d'azole en tant qu'inhibiteurs de la voie wnt |
| US20110144049A1 (en) * | 2009-10-21 | 2011-06-16 | Serebruany Victor L | Treating Cardiac Arrhythmias, Heart Failure, Peripheral Artery Disease and Stroke with Cyclopentyl-Triazolo-Pyrimidine or Derivative Thereof |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| JP5775094B2 (ja) * | 2009-12-29 | 2015-09-09 | イーライ リリー アンド カンパニー | 統合失調症の処置に有用な選択的ｍＧｌｕ５受容体増強因子としてのテトラヒドロトリアゾロピリジン化合物 |
| ES2586231T3 (es) * | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| EP2560488B1 (fr) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| WO2011137206A1 (fr) | 2010-04-30 | 2011-11-03 | Novartis Ag | Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs) |
| WO2012006760A1 (fr) * | 2010-07-14 | 2012-01-19 | Merck Sharp & Dohme Corp. | Composés tricycliques comme modulateurs allostériques des récepteurs métabotropes au glutamate |
| UA112418C2 (uk) | 2010-09-07 | 2016-09-12 | Астеллас Фарма Інк. | Терапевтичний болезаспокійливий засіб |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| WO2012058128A2 (fr) * | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Modulateurs caprolactames des récepteurs mglur5 |
| CN103429583A (zh) | 2010-12-08 | 2013-12-04 | 奥斯陆大学医院公司 | 作为wnt信号通路抑制剂的三唑衍生物 |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| US9139576B2 (en) | 2011-05-03 | 2015-09-22 | Merck Sharp & Dohme Corp. | Aminomethyl biaryl benzotriazole derivatives |
| US8592423B2 (en) | 2011-06-21 | 2013-11-26 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| EP2545964A1 (fr) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité |
| WO2013131981A1 (fr) | 2012-03-08 | 2013-09-12 | Novartis Ag | Marqueurs de prédiction utiles dans le diagnostic et le traitement du syndrome de l'x fragile (fxs) |
| US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| EP2922847A1 (fr) | 2012-11-20 | 2015-09-30 | Vertex Pharmaceuticals Incorporated | Composés utiles comme inhibiteurs de l'indoléamine 2,3-dioxygénase |
| US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
| CN105636953B (zh) | 2013-07-31 | 2018-01-02 | 诺华股份有限公司 | 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 |
| CN107207488B (zh) | 2014-12-17 | 2020-11-17 | 伦敦皇家学院 | 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物 |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| EP3159332A1 (fr) | 2015-10-23 | 2017-04-26 | Ludwig-Maximilians-Universität München | 5,5'-bis(2,4,6-trinitrophenyle)-2,2'-bi(1,3,4-oxadiazole) et bis(2,4,6-trinitrobenzoyle)oxalohydrazide |
| CA2968836C (fr) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | Composes modulant fxr (nr1h4) |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| ES2982801T3 (es) | 2017-03-28 | 2024-10-17 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas |
| MY202326A (en) | 2017-09-14 | 2024-04-24 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
| BR112020009361A2 (pt) | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| KR102692309B1 (ko) | 2019-01-15 | 2024-08-07 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
| WO2020172075A1 (fr) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Formes solides d'agonistes de fxr |
| EP3771711A1 (fr) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Dérivés de pyrazole pour le contrôle des arthropodes |
| CN111362934A (zh) * | 2020-04-21 | 2020-07-03 | 南开大学 | 一类异噻唑联噁二唑衍生物及其制备方法和用途 |
| IL316907A (en) | 2022-05-16 | 2025-01-01 | Sparrow Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS |
| HRP20251564T1 (hr) | 2022-05-19 | 2026-01-30 | Astrazeneca Ab | Amidni heteroaromatski spojevi korisni u liječenju bolesti jetre |
| CN115716822B (zh) * | 2022-11-14 | 2025-05-16 | 徐州医科大学 | 苯并咪唑基异噁唑类化合物在制备与多发性骨髓瘤有关药物方面的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740434A (en) * | 1966-12-23 | 1973-06-19 | American Cyanamid Co | Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents |
| US3816426A (en) * | 1970-10-27 | 1974-06-11 | Abbott Lab | 1-(5-phenyl-4-oxo-2-oxazolin-2-yl)piperazines |
| JPS56127364A (en) | 1980-03-01 | 1981-10-06 | Mitsui Toatsu Chem Inc | Novel piperazine compound, its preparation and utilization |
| JP3003148B2 (ja) | 1989-01-05 | 2000-01-24 | 藤沢薬品工業株式会社 | チアゾール化合物、その製造法およびそれを含有する医薬組成物 |
| US5140034A (en) * | 1989-03-14 | 1992-08-18 | Merck Sharp & Dohme Ltd. | Five-membered ring systems with bonded imidazolyl ring substituents |
| US4914207A (en) * | 1989-05-09 | 1990-04-03 | Pfizer Inc. | Arylthiazolylimidazoles |
| DE3929673A1 (de) * | 1989-09-07 | 1991-03-14 | Bayer Ag | Substituierte carbamoyltriazole |
| IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| AU678186B2 (en) * | 1992-10-23 | 1997-05-22 | Merck Sharp & Dohme Limited | Dopamine receptor subtype ligands |
| DE19643037A1 (de) * | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| DE19858193A1 (de) * | 1998-12-17 | 2000-06-21 | Aventis Cropscience Gmbh | 4-Trifluormethyl-3-oxadiazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
| DE19725450A1 (de) | 1997-06-16 | 1998-12-17 | Hoechst Schering Agrevo Gmbh | 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclylpyrimidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
| AU771358B2 (en) * | 1997-11-21 | 2004-03-18 | Astrazeneca Ab | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| DE19858192A1 (de) * | 1998-12-17 | 2000-06-21 | Aventis Cropscience Gmbh | 4-Trifluormethyl-3-oxazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
| DE19858191A1 (de) | 1998-12-17 | 2000-06-21 | Aventis Cropscience Gmbh | 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclyl-pyrimidine und ihre Verwendung als Repellentien |
| CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
| ATE307129T1 (de) | 1999-08-19 | 2005-11-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren |
| EP1223932A4 (fr) * | 1999-10-01 | 2003-01-15 | Smithkline Beecham Corp | Composes et methodes |
| TWI283577B (en) | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
| DE19962901A1 (de) | 1999-12-23 | 2001-07-05 | Aventis Cropscience Gmbh | Azolylalkalylazol-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
| WO2002024680A1 (fr) | 2000-09-21 | 2002-03-28 | Smithkline Beecham P.L.C. | Derives d'imidazole en tant qu'inhibiteurs de la raf kinase |
| NZ525917A (en) | 2000-12-04 | 2005-11-25 | F | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders |
| MXPA04000565A (es) | 2001-07-19 | 2005-06-17 | Cv Therapeutics Inc | Compuestos de piperazina sustituidos y su uso como inhibidores de oxidacion de acidos grasos. |
| WO2004014881A2 (fr) * | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | Nouveaux composes |
| WO2005077345A1 (fr) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Composes pour le traitement de la maladie du reflux gastro-oesophagien |
| ATE402935T1 (de) | 2004-02-18 | 2008-08-15 | Astrazeneca Ab | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
-
2003
- 2003-08-08 WO PCT/US2003/024846 patent/WO2004014881A2/fr not_active Ceased
- 2003-08-08 MX MXPA05001594A patent/MXPA05001594A/es active IP Right Grant
- 2003-08-08 JP JP2004527872A patent/JP4637578B2/ja not_active Expired - Fee Related
- 2003-08-08 US US10/637,012 patent/US20040152699A1/en not_active Abandoned
- 2003-08-08 BR BR0313265-0A patent/BR0313265A/pt not_active Application Discontinuation
- 2003-08-08 CN CN200910208474A patent/CN101723941A/zh active Pending
- 2003-08-08 RU RU2005106844/04A patent/RU2352568C9/ru not_active IP Right Cessation
- 2003-08-08 IL IL16651003A patent/IL166510A0/xx unknown
- 2003-08-08 AU AU2003259068A patent/AU2003259068B2/en not_active Ceased
- 2003-08-08 EP EP03785036A patent/EP1529045A2/fr not_active Withdrawn
- 2003-08-08 PL PL03375256A patent/PL375256A1/xx unknown
- 2003-08-08 NZ NZ538225A patent/NZ538225A/en not_active IP Right Cessation
- 2003-08-08 TW TW092121880A patent/TWI341314B/zh not_active IP Right Cessation
- 2003-08-08 AR AR20030102891A patent/AR040847A1/es unknown
- 2003-08-08 CN CNA038238454A patent/CN1894241A/zh active Pending
- 2003-08-08 UA UAA200501100A patent/UA87653C2/ru unknown
- 2003-08-08 CA CA2494987A patent/CA2494987C/fr not_active Expired - Fee Related
- 2003-08-08 KR KR1020057002101A patent/KR20050033070A/ko not_active Ceased
-
2005
- 2005-01-31 ZA ZA200500886A patent/ZA200500886B/en unknown
- 2005-03-09 IS IS7733A patent/IS7733A/is unknown
- 2005-03-09 NO NO20051225A patent/NO20051225L/no unknown
- 2005-11-14 US US11/274,611 patent/US7456200B2/en not_active Expired - Fee Related
-
2010
- 2010-06-14 JP JP2010135508A patent/JP2010248214A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR0313265A (pt) | 2005-07-05 |
| WO2004014881B1 (fr) | 2004-07-15 |
| US7456200B2 (en) | 2008-11-25 |
| AU2003259068B2 (en) | 2009-07-02 |
| CN1894241A (zh) | 2007-01-10 |
| RU2352568C9 (ru) | 2009-06-27 |
| CN101723941A (zh) | 2010-06-09 |
| CA2494987C (fr) | 2012-04-17 |
| AR040847A1 (es) | 2005-04-20 |
| RU2005106844A (ru) | 2005-08-27 |
| CA2494987A1 (fr) | 2004-02-19 |
| AU2003259068A1 (en) | 2004-02-25 |
| IS7733A (is) | 2005-03-09 |
| UA87653C2 (en) | 2009-08-10 |
| NZ538225A (en) | 2008-05-30 |
| ZA200500886B (en) | 2006-07-26 |
| IL166510A0 (en) | 2006-01-15 |
| EP1529045A2 (fr) | 2005-05-11 |
| US20040152699A1 (en) | 2004-08-05 |
| JP4637578B2 (ja) | 2011-02-23 |
| TW200413361A (en) | 2004-08-01 |
| MXPA05001594A (es) | 2005-09-20 |
| PL375256A1 (en) | 2005-11-28 |
| RU2352568C2 (ru) | 2009-04-20 |
| KR20050033070A (ko) | 2005-04-08 |
| US20060122397A1 (en) | 2006-06-08 |
| WO2004014881A3 (fr) | 2004-05-27 |
| JP2006503009A (ja) | 2006-01-26 |
| JP2010248214A (ja) | 2010-11-04 |
| TWI341314B (en) | 2011-05-01 |
| WO2004014881A2 (fr) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20051223L (no) | Oksadiazoler som modulatorer av metabotropisk glutamat reseptor-5. | |
| SE0200920D0 (sv) | Novel compounds | |
| NO20054329L (no) | Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike | |
| NO20051962L (no) | Fenetanolaminderivater for behandling av respiratoriske sykdommer | |
| GEP20074197B (en) | 5ht2c receptor modulators | |
| MXPA04007414A (es) | Indoles sustituidos como agonistas alfa-1. | |
| WO2004014902A8 (fr) | Nouveaux composes | |
| NO20044826L (no) | Pyrrolidinderivater | |
| NO20070570L (no) | Forbindelser. | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| IS2376B (is) | Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi | |
| NO20045486L (no) | Nye forbindelser og deres anvendelse | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| NO20071314L (no) | Peptidiske vasopressinreseptoragonister | |
| NO20055977L (no) | Nye benzimidazolderivater | |
| NO20050134L (no) | Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse | |
| CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
| ATE482933T1 (de) | Sulfopyrrolderivate | |
| NO20034215D0 (no) | Nye amider, fremstilling og terapeutisk anvendelse av modulatorer av CCR-reseptoraktivitet | |
| NO20044531L (no) | Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom | |
| NO20026081L (no) | Nye forbindelser | |
| NO20060383L (no) | Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister | |
| MXPA05011521A (es) | Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104 |
|
| CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA |